We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Madrigal Pharmaceuticals Inc
2 own
4 watching
Current Price
$289.07
$0.82
(0.28%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
4,944.08M
52-Week High
315.45
52-Week Low
57.1534
Average Volume
0.2M
Dividend Yield
--
P/E Ratio
--
Market Capitalization4,944.08M52-Week High315.4552-Week Low57.1534Average Volume0.2MDividend Yield--P/E Ratio--What does the Madrigal Pharmaceuticals Inc do?
Synta Pharmaceuticals Corp. focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its clinical stage drug candidate in oncology is ganetespib, an Hsp90 inhibitor, which is in Phase II clinical trials to evaluate the combination of ganetespib and paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including malignant peripheral nerve sheath tumors. The company's drug candidate in its Hsp90-inhibitor Drug Conjugate program is STA-12-8666, which is in preclinical trials for chemotherapy irinotecan. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
Read More
How much money does Madrigal Pharmaceuticals Inc make?
News & Events about Madrigal Pharmaceuticals Inc.
Zolmax
11days ago
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) Director Richard S. Levy sold 22,489 shares of the businesss stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $293.15, for a total transaction of $6,592,650.35. Following ...
Ticker Report
18days ago
StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL Get Rating) from a sell rating to a hold rating in a research note released on Thursday morning. MDGL has been the topic of a number of other research reports. Evercore ISI upped their target price on Madrigal ...
Ticker Report
24days ago
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) SVP Brian Joseph Lynch sold 13,000 shares of the firms stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $282.92, for a total transaction of $3,677,960.00. The transaction was...
Globe Newswire
27days ago
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint ...
Ticker Report
1month ago
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) insider Remy Sukhija sold 30,000 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, December 23rd. The shares were sold at an average price of $274.14, for a total value of $8,224,200.00. The transaction was ...
Frequently Asked Questions
Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc share price today?
Can Indians buy Madrigal Pharmaceuticals Inc shares?
How can I buy Madrigal Pharmaceuticals Inc shares from India?
Can Fractional shares of Madrigal Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Madrigal Pharmaceuticals Inc stocks?
What is today’s traded volume of Madrigal Pharmaceuticals Inc?
What is today’s market capitalisation of Madrigal Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Madrigal Pharmaceuticals Inc?
What percentage is Madrigal Pharmaceuticals Inc down from its 52-Week High?
What percentage is Madrigal Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$289.07
$0.82
(0.28%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.